In a 7-year extension of a randomised trial, 59 adults with HIV took efavirenz/emtricitabine/tenofovir DF three days a week: 63% remained free of treatment failure, with one virological failure; most failures were discontinuations.
RCTn = 59
Borjabad et al. Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study